IMA — ImageneBio, Inc.
NASDAQ · Healthcare · Biotechnology
$5.40
+$0.38 (+7.57%)
ImageneBio, Inc. (IMA) is a biotechnology company listed on NASDAQ. It is led by Kristin Yarema Ph.D., based in 12526 High Bluff Drive, San Diego, CA, United States, 92130, with about 17 employees. ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Latest reported IMA revenue for 2025-09-30 was $800.0K. Net income was -$38.4M. IMA currently screens at market cap $64.7M.
Use this IMA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IMA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IMA SEC filings page. Lician reads the product cache first so this HTML stays unique to ImageneBio, Inc. even when a live quote feed is slow.
About ImageneBio, Inc.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
IMA Key Statistics
Market Cap
$64.74M
Volume
16,675
Previous Close
$5.62
Day Range
$5.44 – $5.62
P/B Ratio
0.52
EPS
-$1.02
Revenue
$0.00
Net Income
-$49.23M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-100.0%
Employees
17
IMA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $9.16M | $15.62M | $30.98M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$49.23M | -$68.17M | -$68.77M | -$34.12M |
| EPS (Diluted) | -$1.02 | -$1.63 | -$1.90 | -$1.22 |
Total Assets
$141.51M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$39.39M
Operating Cash Flow
-$46.00M
Free Cash Flow
$0.00
ImageneBio, Inc. Company Information
- CEO, Director & Interim Principal Financial Officer
- Kristin Yarema Ph.D.
- Headquarters
- 12526 High Bluff Drive, San Diego, CA, United States, 92130
- Website
- www.inmagenebio.com
- Phone
- 858 345 6265
- IPO / Founded
- 2021-03-26
- Sector
- Healthcare
- Industry
- Biotechnology